Organovo Holdings Newsroom

Organovo Holdings Gains Approval for Key Strategic Moves

TipRanksNov 22 08:28 ET

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

BenzingaNov 20 08:08 ET

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

GlobeNewswireNov 20 08:05 ET

Organovo Holdings | 10-Q: Q2 2025 Earnings Report

SECNov 8 16:11 ET · Announcements

Organovo Holdings Files for Offering of Stock and Warrants

Dow JonesOct 25 17:09 ET

Organovo Holdings Grants Stock Options to Executive Chairman

TipRanksAug 9 16:30 ET

Organovo Holdings | 10-Q: Q1 2025 Earnings Report

SECAug 5 16:09 ET · Announcements

Organovo Holdings | 10-K/A: Annual report (Amendment)

SECJul 26 16:09 ET · Announcements

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

BenzingaJul 18 07:55 ET

Express News | Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

BenzingaJul 16 08:07 ET

Organovo Holdings | 10-K: FY2024 Annual Report

SECMay 31 16:10 ET · Announcements

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy With Tofacitinib for Inflammatory Bowel Disease

GlobeNewswireMay 21 08:05 ET

Express News | Organovo Granted U.S. Patent #11982668: Use Of Engineered Renal Tissues In Assays

BenzingaMay 14 12:56 ET

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

GlobeNewswireMay 14 11:00 ET

Express News | Organovo Holdings Shares Are Trading Lower After the Company Announced the Pricing of a $5.25 Million Public Offering of 6,562,500 Shares and Common Warrants

BenzingaMay 9 08:20 ET

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

BenzingaMay 9 08:13 ET

Express News | Reported Earlier, Organovo Prices $5.25M Public Offering Of 6,562,500 Common Shares And Common Warrants At A Combined Price Of $0.80

BenzingaMay 9 04:43 ET

Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of 6,562,500 Shares Of Common Stock And Common Warrants At A Combined Price Of $0.80

BenzingaMay 8 20:09 ET

Organovo Holdings' Offering of 6.6 Million Shares and Warrants Prices at 80 Cents a Share and Warrant

Dow JonesMay 8 20:03 ET

Organovo Holdings Announces Pricing of $5.25M Public Offering

Dow JonesMay 8 20:02 ET